Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CT
CytomX Therapeutics, Inc.
CTMX
Mkt Cap
$495.7M
Volume
2.83M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CT
CTMX
CT
CytomX Therapeutics, Inc.
CTMX
News
·
CytomX Therapeutics to Present at Upcoming September Investor Conferences
Mkt Cap
$525.1M
Volume
2.83M
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics announced that management will participate in three major healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global Healthcare, and Morgan Stanley conferences. The company will host fireside chats and one-on-one investor meetings at these events. Live webcasts will be available on CytomX's website.
GlobeNewswire Inc. · Sep 1, 2026
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
CytomX Therapeutics expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies combining CytomX's PROBODY platform with Regeneron's Veloci-Bi platform. CytomX will receive $37 million for two additional programs, with potential total milestones reaching approximately $4 billion across up to 6 additional future targets.
GlobeNewswire Inc. · Jun 3, 2026
CytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company developing conditionally activated masked PROBODY therapeutics for oncology, with lead candidates including varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.
GlobeNewswire Inc. · May 21, 2026
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
The article compares small-cap and megacap healthcare stocks, using CytomX Therapeutics and Johnson & Johnson as examples. Small-cap stocks like CTMX offer higher growth potential but carry significant risk with no approved drugs and substantial losses. Megacap stocks like JNJ provide stability, consistent revenue growth, and dividend payments, though with lower explosive upside potential. The choice depends on individual investment goals and risk tolerance.
The Motley Fool · Apr 22, 2026
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
CytomX Therapeutics priced a $250 million underwritten public offering of 45.99 million shares at $5.30 per share and pre-funded warrants. The company plans to use net proceeds for development of Varseta-M and other pipeline programs. The offering is expected to close on March 19, 2026.
GlobeNewswire Inc. · Mar 18, 2026
CytomX Therapeutics to Present at Upcoming February Conferences
CytomX Therapeutics announced that management will participate in two upcoming conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 in New York and World ADC London on February 25 in London. The clinical-stage biopharmaceutical company, focused on conditionally activated biologics for oncology, continues to advance its pipeline including varsetatug masetecan and CX-801.
GlobeNewswire Inc. · Feb 4, 2026
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference
CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced upcoming presentations of its clinical-stage pipeline including CX-2051 and CX-801, with Phase 1 data updates expected in early 2026.
GlobeNewswire Inc. · Nov 13, 2025
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 p.m. ET.
GlobeNewswire Inc. · Oct 30, 2025
12 Health Care Stocks Moving In Thursday's After-Market Session
Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.
Benzinga · Sep 25, 2025
CytomX (CTMX) Q2 Revenue Drops 26%
CytomX Therapeutics reported Q2 2025 results with declining revenue, reduced operating expenses, and positive clinical pipeline progress, particularly for its lead colorectal cancer candidate CX-2051.
The Motley Fool · Aug 7, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CT
CTMX
CytomX Therapeutics, Inc.
Buy
Sell
Market
Limit
Soon
CTMX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CTMX yet.
Related Tickers
Earnings